Back to Prescriptions

When a Shortage Becomes Permanent

When a Shortage Becomes Permanent
Prescription Medicines Editorial 27 December 2024

A shortage is usually temporary. Occasionally it is not - the manufacturer decides not to resume, a plant closes for good, or a product is withdrawn commercially. What makes this awkward is that nobody announces the transition. People are switched on the understanding that it is temporary, and only months later does it become clear the original is not coming back.

Why medicines disappear permanently

Commercial withdrawal - the commonest reason. An old generic with a low price and a small market stops being worth making, particularly where only one or two manufacturers remain.

A manufacturing problem that makes resuming uneconomic.

Regulatory action on safety grounds - which is rare, and usually announced clearly.

Supersession by a newer product.

Note the pattern: a medicine becoming very cheap is what makes it fragile, not what makes it secure. When competition collapses to one supplier, a single problem removes the entire supply.

See why medicines get discontinued and what happens when a patent expires.

Find out which situation you are in

This is the practical step, and it takes one question.

Ask the pharmacy whether the product has been discontinued or is temporarily unavailable. They will know, or can find out from the wholesaler.

The answer changes everything. A temporary gap justifies a short-term substitution and switching back later. A discontinuation means the switch is permanent and should be treated as a proper change of treatment.

Treating a permanent change as temporary is how people end up on something nobody has reviewed, waiting indefinitely for a return.

See how shortages are communicated.

Treat a permanent switch as a new medicine

Because that is what it is.

Ask what the alternative is and how it differs. Ask whether the dose is equivalent - alternatives within a class are rarely interchangeable milligram for milligram.

Ask whether monitoring changes, and whether any new blood test is needed.

Ask what to watch for in the first weeks, and agree a review point.

Make sure your repeat list is updated so the old item is removed - leaving it on generates failed orders indefinitely.

See starting a new medicine.

Where a switch needs real care

Some changes are not simple substitutions.

Certain antiepileptics, where the MHRA categorises which may be switched freely and which should be maintained on one manufacturer's product.

Modified-release preparations, where different release technologies produce different profiles from the same nominal dose.

Lithium, where preparations are genuinely not equivalent.

Inhalers, where the device and technique change even when the drug does not - and aerosol and dry powder devices need opposite breathing techniques.

Opioids and other controlled drugs, where conversion is a specialist calculation.

For these, the switch is a prescriber decision rather than a substitution the pharmacy can make.

See when your inhaler or device changes.

If no alternative exists

Occasionally there is no licensed equivalent - most often with older products, unusual strengths or specific formulations.

Options then include an unlicensed import of the same product from another country, or a special made to order.

Both are slow, expensive to the NHS, and carry practical consequences - particularly that the strength of a special can vary between suppliers, so the volume you measure may change.

Where a condition is rare, the relevant patient organisation is frequently the best source of information and sometimes the most effective route to pressure for continued supply.

See unlicensed specials and imported medicines.

Keep a record of the transition

During a prolonged shortage people are switched more than once, and the record lags behind reality.

Write down each product, strength and date. It matters if a side effect appears, if you are admitted to hospital, or if someone later asks what you have actually tried.

Report side effects from the new product through the Yellow Card scheme - reporting matters more after a switch, because this is exactly when new problems surface.

See keeping a medicines list.

Tell them if the alternative does not suit

A permanent switch made during a shortage is frequently never reviewed, because the change was framed as administrative rather than clinical.

If control is worse, or side effects have appeared, say so plainly and ask for the alternatives to be reconsidered - there is usually more than one option, and the first substitute chosen under time pressure is not necessarily the best one.

Do not try to source the old one

The temptation to find the discontinued product online is understandable and dangerous.

A site offering stock of something withdrawn from legitimate supply is not a pharmacy, and this is precisely the market falsified medicines circulate in.

See buying medicines through social media.

When a Shortage Affects a Child's Medicine covers a related point, and the Prescriptions section has the rest of these guides.